FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562905044> ?p ?o ?g. }

• W2562905044 abstract "In nearly 90% of cancer cell types, telomere ends are stabilized by inappropriate activation of telomerase, thereby preventing telomeres from sequential shortening and establishing conditions which promote malignant transformation and immortality. As a result, telomeres and telomerase have recently become attractive targets in the development of novel anticancer therapeutics. Administration of an 11-mer oligonucleotide homologous to the 3′ overhang of the telomere, T-oligo, is presumed to mimic or signal for damaged telomeric DNA, thereby inducing inherent telomere-based DNA damage responses. Exposure to T-oligo induces cell cycle arrest, senescence, apoptosis, and differentiation in a cancer cell-type specific manner. Intravenous administration of T-oligo drastically reduces tumor burden in mice. Remarkably, T-oligo has minimal side-effects on normal cells, and has shown no detectable toxicity in in vivo mouse studies. However, as an oligonucleotide, T-oligo has limited stability due to serum and intracellular nucleases. We have previously improved the delivery of T-oligo by complexing it with a novel cationic alpha helical peptide, PVBLG-8, which improved its efficacy both in vitro and in vivo. Moreover, the T-oligo-PVBLG (TOP) nanocomplex demonstrated increased charge stability and diameter in comparison to T-oligo. In this study we have further optimized the TOP¬¬¬ nanocomplex, thereby improving the physiochemical properties of T-oligo for delivery and bringing T-oligo closer to clinical fruition as an innovative, anticancer therapeutic. The binding efficiency of T-oligo and PVBLG was optimized by measuring the amount of naked DNA under a range of nitrogen/phosphorus (N/P) ratios. We then compared the biodistribution of both T-oligo and TOP in vivo at various N/P ratios. T-oligo was conjugated with FITC and intravenously administered to the tail vein of mice in the presence or absence of PVBLG and monitored using molecular imaging. We found that T-oligo distribution was isolated to the kidneys, indicating that its small size makes it susceptible to renal filtration. In contrast, the TOP complex, which has a larger diameter, was able to bypass renal filtration and enter the liver and/or lungs. We also found that PVBLG was able to protect T-oligo from nucleolytic degradation in vitro. ¬¬¬¬In addition, to further elucidate T-oligo9s mechanism of action, we investigated its ability to form G-quadruplexes, since increasing G-quadruplex stability is known to induce apoptosis. G-quadruplex formation by T-oligo was confirmed by NMR and native-PAGE. Furthermore, since increasing G-quadruplex stability is known to activate the SAPK/JNK signaling pathway, we also investigated T-oligo9s effect on the SAP/JNK pathway using immunoblotting. Collectively, these studies will significantly advance the therapeutic utility of T-oligo against melanoma. Citation Format: Luke Wojdyla, Neelu Puri. Nanotechnology delivery and mechanism of action of telomere oligonucleotides in melanoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3679. doi:10.1158/1538-7445.AM2015-3679" @default.
• W2562905044 created "2017-01-06" @default.
• W2562905044 creator A5034098442 @default.
• W2562905044 creator A5081781260 @default.
• W2562905044 date "2015-08-01" @default.
• W2562905044 modified "2023-09-25" @default.
• W2562905044 title "Abstract 3679: Nanotechnology delivery and mechanism of action of telomere oligonucleotides in melanoma" @default.
• W2562905044 doi "https://doi.org/10.1158/1538-7445.am2015-3679" @default.
• W2562905044 hasPublicationYear "2015" @default.
• W2562905044 type Work @default.
• W2562905044 sameAs 2562905044 @default.
• W2562905044 citedByCount "0" @default.
• W2562905044 crossrefType "proceedings-article" @default.
• W2562905044 hasAuthorship W2562905044A5034098442 @default.
• W2562905044 hasAuthorship W2562905044A5081781260 @default.
• W2562905044 hasConcept C104317684 @default.
• W2562905044 hasConcept C121608353 @default.
• W2562905044 hasConcept C129312508 @default.
• W2562905044 hasConcept C143425029 @default.
• W2562905044 hasConcept C153911025 @default.
• W2562905044 hasConcept C177336024 @default.
• W2562905044 hasConcept C185592680 @default.
• W2562905044 hasConcept C207001950 @default.
• W2562905044 hasConcept C502942594 @default.
• W2562905044 hasConcept C54355233 @default.
• W2562905044 hasConcept C552990157 @default.
• W2562905044 hasConcept C55493867 @default.
• W2562905044 hasConcept C86803240 @default.
• W2562905044 hasConcept C94581717 @default.
• W2562905044 hasConcept C95444343 @default.
• W2562905044 hasConcept C96232424 @default.
• W2562905044 hasConceptScore W2562905044C104317684 @default.
• W2562905044 hasConceptScore W2562905044C121608353 @default.
• W2562905044 hasConceptScore W2562905044C129312508 @default.
• W2562905044 hasConceptScore W2562905044C143425029 @default.
• W2562905044 hasConceptScore W2562905044C153911025 @default.
• W2562905044 hasConceptScore W2562905044C177336024 @default.
• W2562905044 hasConceptScore W2562905044C185592680 @default.
• W2562905044 hasConceptScore W2562905044C207001950 @default.
• W2562905044 hasConceptScore W2562905044C502942594 @default.
• W2562905044 hasConceptScore W2562905044C54355233 @default.
• W2562905044 hasConceptScore W2562905044C552990157 @default.
• W2562905044 hasConceptScore W2562905044C55493867 @default.
• W2562905044 hasConceptScore W2562905044C86803240 @default.
• W2562905044 hasConceptScore W2562905044C94581717 @default.
• W2562905044 hasConceptScore W2562905044C95444343 @default.
• W2562905044 hasConceptScore W2562905044C96232424 @default.
• W2562905044 hasLocation W25629050441 @default.
• W2562905044 hasOpenAccess W2562905044 @default.
• W2562905044 hasPrimaryLocation W25629050441 @default.
• W2562905044 hasRelatedWork W1964943248 @default.
• W2562905044 hasRelatedWork W1965743650 @default.
• W2562905044 hasRelatedWork W1973996994 @default.
• W2562905044 hasRelatedWork W1984912016 @default.
• W2562905044 hasRelatedWork W1991205530 @default.
• W2562905044 hasRelatedWork W2010141165 @default.
• W2562905044 hasRelatedWork W2013971815 @default.
• W2562905044 hasRelatedWork W2021636842 @default.
• W2562905044 hasRelatedWork W2028621966 @default.
• W2562905044 hasRelatedWork W2038565376 @default.
• W2562905044 hasRelatedWork W2047333232 @default.
• W2562905044 hasRelatedWork W2050366181 @default.
• W2562905044 hasRelatedWork W2117084476 @default.
• W2562905044 hasRelatedWork W2134600910 @default.
• W2562905044 hasRelatedWork W2163867676 @default.
• W2562905044 hasRelatedWork W2351765653 @default.
• W2562905044 hasRelatedWork W2415670545 @default.
• W2562905044 hasRelatedWork W2607022649 @default.
• W2562905044 hasRelatedWork W2906794778 @default.
• W2562905044 hasRelatedWork W2815688990 @default.
• W2562905044 isParatext "false" @default.
• W2562905044 isRetracted "false" @default.
• W2562905044 magId "2562905044" @default.
• W2562905044 workType "article" @default.